Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 6/20 | 0.48 |
| ▸ | NPC1 | O15118 | 5/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | METAP2 | P50579 | 1/20 | 0.43 |
| ▸ | METAP1 | P53582 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6606083 | 0.89 | MEN1 (0.48) | RAB9ANPC1SMN1; SMN2HDAC6HDAC1 | |
| SCHEMBL13543523 | 0.81 | RAB9A (0.54) | RAB9ANPC1SMN1; SMN2HDAC6HDAC1 | |
| SCHEMBL30589360 | 0.78 | CHEK2 (0.52) | SMN1; SMN2KDM4EKMT2A | |
| SCHEMBL31140559 | 0.76 | LGALS8 (0.45) | — | |
| SCHEMBL459471 | 0.75 | SMN1; SMN2 (0.57) | RAB9ANPC1SMN1; SMN2ATMKDM4E | |
| SCHEMBL30189629 | 0.75 | SMN1; SMN2 (0.57) | RAB9ANPC1SMN1; SMN2ATMKDM4E | |
| SCHEMBL11404384 | 0.72 | RAB9A (0.51) | RAB9ANPC1SMN1; SMN2HDAC6ATM | |
| SCHEMBL28236281 | 0.72 | SMN1; SMN2 (0.49) | RAB9ANPC1SMN1; SMN2HDAC6ATM | |
| SCHEMBL15987069 | 0.71 | ATM (0.53) | RAB9ANPC1SMN1; SMN2ATMKDM4E | |
| SCHEMBL4728786 | 0.71 | HDAC6 (0.67) | RAB9ANPC1SMN1; SMN2HDAC6KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2602255-B1 | FUSED HETEROCYCLIC RING COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2017-04-26 | — | — | EP | disclosed |
| US-8883788-B2 | Fused heterocyclic ring compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-11-11 | — | — | US | disclosed |
| EP-2602255-A1 | FUSED HETEROCYCLIC RING COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2013-06-12 | — | — | EP | disclosed |
| US-20130137700-A1 | FUSED HETEROCYCLIC RING COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130137700-A1 | FUSED HETEROCYCLIC RING COMPOUND | PDE10A, PDE3A, PDE2A | RAB9A 39/4885NPC1 3226/4885SMN1; SMN2 3406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.